Navigation Links
Spectros Corporation Year-To-Date Oximeter Sales Revenue Up 51% in First Half of 2011
Date:7/29/2011

PORTOLA VALLEY, Calif., July 29, 2011 /PRNewswire/ -- Spectros Corporation announced today that 2011 year-to-date sales revenue rose 51% (year-over-year) over the similar period in 2010. This continues the third year in a row for double-digit revenue growth for Spectros since the current T-Stat Tissue Oximeter product line was launched in 2008.

"This growth sends a clear signal that the market is embracing the Spectros state-of-the-art broadband VLS tissue oximetry," notes CFO John Bagnatori.

Spectros T-Stat® and Continuum® Tissue Oximeters are the only broadband tissue oximeters on the market in the U.S. and Europe. T-Stat® and Continuum® compete in the marketplace with INVOS® oximeters marketed by Covidien. An expanded array of probes, including Continuum® broadband cerebral probes currently being readied for manufacturing, pending FDA approval and release anticipated over the next year.

About Spectros

Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat VLS Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue.  T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art multispectral visible light spectroscopy (VLS) technology.  The non-invasive T-Stat VLS system is used clinically to provide a continuous and real-time absolute value, utilizing 260 wavelengths, over the competing NIRS oximeter product lines that only use 2-4.

Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute.  Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

(Note:  Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns.  Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled for investigational use only.  T-Stat and Continuum are trademarks of the Spectros Corporation. INVOS is a trademark of Somanetics and Covidien).

For further information, visit www.spectros.com.


'/>"/>
SOURCE Spectros
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Spectros Corporation Introduces Continuum®, a Broadband Infrared Sensor for Brain and Gut Oximetry
2. Spectros Corporation Sales and Licensing Revenue Up 32% in 2010
3. Spectros White LED Patent Scope Affirmed In U.S. Patent Office Reexamination
4. Spectros Presents New Clinical Studies Using T-Stat VLS Tissue Oximeter at Anesthesiology 2010
5. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
6. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
7. Spectros Corp. Enters Into Optical Biotechnology Patent Sale Agreement With Philips Electronics N.V.
8. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
9. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
10. Kensey Nash Corporation Announces Its Fourth Quarter and Fiscal Year End 2011 Earnings Release Date and Teleconference
11. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb. 27, 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... Craig , M.D., Ph.D., as President and Chief Executive Officer ... 20, 2017. Dr. Craig succeeds Richard Love , interim ... company,s Board of Directors.  Dr. Craig has over 20 years ... the US and Europe . ...
(Date:2/27/2017)... N.J. and PETACH TIKVAH, Israel ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... appointments of June S. Almenoff , M.D., Ph.D., ... to its Board of Directors.  "Dr. ... executives whose appointments come at an exciting time for ...
(Date:2/27/2017)... , Feb 27, 2017 Period October – December ... Operating result amounted to SEK -16.4 (-6.4) million ... per share (-0.22) before and after dilution Cash flow from ... ... to SEK 0.4 (0.4) million Operating result amounted to SEK ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... Dr. Ronald E. Hawkins, vice president ... of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean ... Dr. Bell comes to Liberty from the Ohio University Heritage College of Osteopathic ...
(Date:2/24/2017)... ... , ... With millions of Americans and people worldwide struggling ... are aware of our options and are empowered with strength and information throughout ... its newest edition of "Vision and Hearing" in USA Today, that will educate ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... With ProGlass ... Cut Pro X . Users have total control over position, rotation, distortion, edge softness, ... all within Final Cut Pro X. , With ProGlass Prism users are given the ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals (iaedp) ... You See” body image mannequin art competition. Selected from 15 submissions from around the ... revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. ...
(Date:2/24/2017)... Fair Lawn, NJ (PRWEB) , ... February 24, ... ... with robust marketing services, which specializes in thought leadership , media ... email marketing campaigns and services that will be powered through Act-On, an intuitive ...
Breaking Medicine News(10 mins):